{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:08Z","timestamp":1786982768343,"version":"build-2736575974"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40273-026-01594-4","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:40:22Z","timestamp":1770403222000},"page":"559-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-0999","authenticated-orcid":false,"given":"Josep","family":"Darb\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Ascanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"1594_CR1","unstructured":"World Cancer Research Fund. Prostate cancer statistics. https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/prostate-cancer-statistics\/. Accessed 28 Apr 2025."},{"key":"1594_CR2","unstructured":"American Cancer Society. Key statistics for prostate cancer. https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html. Accessed 28 Apr 2025."},{"key":"1594_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.021","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021.","journal-title":"Eur Urol"},{"key":"1594_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.11.013","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2025. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013.","journal-title":"Eur Urol"},{"key":"1594_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2021.102093","author":"T Pathirana","year":"2022","unstructured":"Pathirana T, Sequeira R, Del Mar C, Dickinson JA, Armstrong BK, Bell KJL, et al. Trends in prostate specific antigen (PSA) testing and prostate cancer incidence and mortality in Australia: a critical analysis. Cancer Epidemiol. 2022. https:\/\/doi.org\/10.1016\/j.canep.2021.102093.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"1594_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/aja.2008.19","volume":"11","author":"N Borley","year":"2009","unstructured":"Borley N, Feneley MR. Prostate cancer: diagnosis and staging. Asian J Androl. 2009;11(1):74\u201380. https:\/\/doi.org\/10.1038\/aja.2008.19.","journal-title":"Asian J Androl"},{"key":"1594_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.56825","author":"EL Van Blarigan","year":"2025","unstructured":"Van Blarigan EL, McKinley MA, Washington SL 3rd, Cooperberg MR, Kenfield SA, Cheng I, et al. Trends in prostate cancer incidence and mortality rates. JAMA Netw Open. 2025. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56825.","journal-title":"JAMA Netw Open"},{"key":"1594_CR8","unstructured":"Mayo Clinic. Prostate cancer. Diagnosis and Treatment. https:\/\/www.mayoclinic.org\/diseases-conditions\/prostate-cancer\/diagnosis-treatment\/drc-20353093. Accessed 28 Apr 2025."},{"key":"1594_CR9","unstructured":"Cornford P, Tilki D, van den Bergh RCN, Eberli D, De Meerleer G, De Santis M, Gillessen S, Henry AM, van Leenders GJLH, Oldenburg J, Oprea-Lager DE, Roberts M, Rouvi\u00e8re O, Schoots IG, Stranne J, Wiegel T, Briers E, Chiu P, Farolfi A, Gandaglia G, Grivas N, Linares Espin\u00f3s E, Sachdeva A, Smith EJ, Bezuidenhout C. EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5."},{"key":"1594_CR10","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer (Version 3.2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 28 Apr 2025."},{"key":"1594_CR11","unstructured":"National Cancer Control Programme. (2025). HSE National Clinical Guideline: Active surveillance for patients with prostate cancer (Version 0). Health Service Executive. https:\/\/assets.hse.ie\/media\/documents\/ncr\/20250410_NCG_Active_Surveillance_Prostate_Cancer.pdf. Accessed 28 Apr 2025."},{"key":"1594_CR12","unstructured":"National Cancer Control Programme. (2025). HSE National Clinical Guideline: The Use of Focal Therapy in Patients with Prostate Cancer (Version 0). Health Service Executive. https:\/\/assets.hse.ie\/media\/documents\/ncr\/20250410_NCG_Use_of_Focal_Therapy_Patients_with_Prostate_Cancer.pdf. Accessed 28 Apr 2025."},{"key":"1594_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000002757","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022. https:\/\/doi.org\/10.1097\/ju.0000000000002757.","journal-title":"J Urol"},{"key":"1594_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000002758","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up. J Urol. 2022. https:\/\/doi.org\/10.1097\/ju.0000000000002758.","journal-title":"J Urol"},{"key":"1594_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000002759","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: principles of radiation and future directions. J Urol. 2022. https:\/\/doi.org\/10.1097\/ju.0000000000002759.","journal-title":"J Urol"},{"key":"1594_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003452","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023. https:\/\/doi.org\/10.1097\/ju.0000000000003452.","journal-title":"J Urol"},{"key":"1594_CR17","doi-asserted-by":"publisher","DOI":"10.1159\/000521882","author":"A Borkowetz","year":"2022","unstructured":"Borkowetz A, Blana A, B\u00f6hmer D, Cash H, Ehrmann U, Franiel T, et al. German S3 evidence-based guidelines on focal therapy in localized prostate cancer: the first evidence-based guidelines on focal therapy. Urol Int. 2022. https:\/\/doi.org\/10.1159\/000521882.","journal-title":"Urol Int"},{"key":"1594_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2022.07.148","author":"G Ploussard","year":"2022","unstructured":"Ploussard G, Fiard G, Barret E, Brureau L, Cr\u00e9hange G, Dariane C, et al. French AFU cancer committee guidelines\u2014update 2022\u20132024: prostate cancer\u2014diagnosis and management of localised disease. Prog Urol. 2022. https:\/\/doi.org\/10.1016\/j.purol.2022.07.148.","journal-title":"Prog Urol"},{"key":"1594_CR19","unstructured":"National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management (NICE Guideline NG131). 2021. https:\/\/www.nice.org.uk\/guidance\/ng131\/resources\/prostate-cancer-diagnosis-and-management-pdf-66141714312133. Accessed 28 Apr 2025."},{"key":"1594_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"issue":"9","key":"1594_CR21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/s44321-025-00282-8","volume":"17","author":"S Nouruzi","year":"2025","unstructured":"Nouruzi S, Kobelev M, Tabrizian N, Gleave M, Zoubeidi A. New frontiers in prostate cancer treatment from systemic therapy to targeted therapy. EMBO Mol Med. 2025;17(9):2191\u2013214. https:\/\/doi.org\/10.1038\/s44321-025-00282-8.","journal-title":"EMBO Mol Med"},{"key":"1594_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2437-3","author":"MS Broder","year":"2015","unstructured":"Broder MS, Gutierrez B, Cherepanov D, Linhares Y. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer. 2015. https:\/\/doi.org\/10.1007\/s00520-014-2437-3.","journal-title":"Support Care Cancer"},{"key":"1594_CR23","doi-asserted-by":"publisher","DOI":"10.5539\/gjhs.v8n4p1","author":"J Norum","year":"2015","unstructured":"Norum J, Traasdahl ER, Totth A, Nieder C, Olsen JA. Health economics and Radium-223 (Xofigo\u00ae) in the treatment of metastatic castration-resistant prostate cancer (mCRPC): a case history and a systematic review of the literature. Glob J Health Sci. 2015. https:\/\/doi.org\/10.5539\/gjhs.v8n4p1.","journal-title":"Glob J Health Sci"},{"key":"1594_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0555-8","author":"J Norum","year":"2017","unstructured":"Norum J, Nieder C. Treatments for metastatic prostate cancer (mPC): a review of costing evidence. Pharmacoeconomics. 2017. https:\/\/doi.org\/10.1007\/s40273-017-0555-8.","journal-title":"Pharmacoeconomics"},{"key":"1594_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208063","author":"T Grochtdreis","year":"2018","unstructured":"Grochtdreis T, K\u00f6nig HH, Dobruschkin A, von Amsberg G, Dams J. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: a systematic review. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0208063.","journal-title":"PLoS ONE"},{"key":"1594_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0448-6","author":"J Smith-Palmer","year":"2019","unstructured":"Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol. 2019. https:\/\/doi.org\/10.1186\/s12894-019-0448-6.","journal-title":"BMC Urol"},{"key":"1594_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174088","author":"D Cantarero-Prieto","year":"2022","unstructured":"Cantarero-Prieto D, Lera J, Lanza-Leon P, Barreda-Gutierrez M, Guillem-Porta V, Castelo-Branco L, et al. The economic burden of localized prostate cancer and insights derived from cost-effectiveness studies of the different treatments. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14174088.","journal-title":"Cancers (Basel)"},{"issue":"19","key":"1594_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193257","volume":"17","author":"I G\u0105ska","year":"2025","unstructured":"G\u0105ska I, Czerw A, Pajewska M, Partyka O, Depta\u0142a A, Badowska-Kozakiewicz A, et al. Direct and indirect costs of prostate cancer: a comprehensive assessment of economic and social impact. Cancers. 2025;17(19):3257. https:\/\/doi.org\/10.3390\/cancers17193257.","journal-title":"Cancers"},{"issue":"1","key":"1594_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","volume":"59","author":"A Heidenreich","year":"2011","unstructured":"Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61\u201371. https:\/\/doi.org\/10.1016\/j.eururo.2010.10.039.","journal-title":"Eur Urol"},{"key":"1594_CR30","unstructured":"International Monetary Fund. https:\/\/www.imf.org. Accessed 28 Apr 2025."},{"key":"1594_CR31","unstructured":"Exchange-rates.org website. https:\/\/www.exchange-rates.org. Accessed 28 Apr 2025."},{"key":"1594_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2020.05.008","author":"AP Lana","year":"2020","unstructured":"Lana AP, Perelman J, Gurgel Andrade EI, Ac\u00farcio F, Guerra AA Jr, Cherchiglia ML. Cost analysis of cancer in Brazil: a population-based study of patients treated by public health system from 2001-2015. Value Health Reg Issues. 2020. https:\/\/doi.org\/10.1016\/j.vhri.2020.05.008.","journal-title":"Value Health Reg Issues"},{"key":"1594_CR33","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.2707","author":"L Perrault","year":"2015","unstructured":"Perrault L, Fradet V, Lauzon V, LeLorier J, Mitchell D, Habib M. Burden of illness of bone metastases in prostate cancer patients in Qu\u00e9bec, Canada: a population-based analysis. Can Urol Assoc J. 2015. https:\/\/doi.org\/10.5489\/cuaj.2707.","journal-title":"Can Urol Assoc J"},{"key":"1594_CR34","doi-asserted-by":"publisher","DOI":"10.3747\/co.23.2953","author":"MD Krahn","year":"2016","unstructured":"Krahn MD, Bremner KE, Luo J, Tomlinson G, Alibhai SM. Long-term health care costs for prostate cancer patients on androgen deprivation therapy. Curr Oncol. 2016. https:\/\/doi.org\/10.3747\/co.23.2953.","journal-title":"Curr Oncol"},{"key":"1594_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29892","author":"C Sanyal","year":"2016","unstructured":"Sanyal C, Aprikian AG, Cury FL, Chevalier S, Dragomir A. Management of localized and advanced prostate cancer in Canada: a lifetime cost and quality-adjusted life-year analysis. Cancer. 2016. https:\/\/doi.org\/10.1002\/cncr.29892.","journal-title":"Cancer"},{"key":"1594_CR36","doi-asserted-by":"publisher","DOI":"10.3747\/co.23.2946","author":"RE Pataky","year":"2016","unstructured":"Pataky RE, Cheung WY, de Oliveira C, Bremner KE, Chan KK, Hoch JS, et al. Population-based trends in systemic therapy use and cost for cancer patients in the last year of life. Curr Oncol. 2016. https:\/\/doi.org\/10.3747\/co.23.2946.","journal-title":"Curr Oncol"},{"key":"1594_CR37","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.5053","author":"F Saad","year":"2019","unstructured":"Saad F, Fleshner NE, So A, Le Lorier J, Perrault L, Poulin-Costello M, et al. The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres. Can Urol Assoc J. 2019. https:\/\/doi.org\/10.5489\/cuaj.5053.","journal-title":"Can Urol Assoc J"},{"key":"1594_CR38","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.5598","author":"A Garbens","year":"2019","unstructured":"Garbens A, Wallis CJD, Matta R, Kodama R, Herschorn S, Narod S, et al. The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer. Can Urol Assoc J. 2019. https:\/\/doi.org\/10.5489\/cuaj.5598.","journal-title":"Can Urol Assoc J"},{"key":"1594_CR39","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5951","author":"N Iragorri","year":"2020","unstructured":"Iragorri N, Essue B, Timmings C, Keen D, Bryant H, Warren GW. The cost of failed first-line cancer treatment related to continued smoking in Canada. Curr Oncol. 2020. https:\/\/doi.org\/10.3747\/co.27.5951.","journal-title":"Curr Oncol"},{"key":"1594_CR40","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20190114","author":"N Mittmann","year":"2020","unstructured":"Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Look Hong NJ, et al. Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. CMAJ Open. 2020. https:\/\/doi.org\/10.9778\/cmajo.20190114.","journal-title":"CMAJ Open"},{"key":"1594_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.01.003","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, Ramaswamy K, Huang A, Sandin R, Mardekian J, Schultz NM, et al. Survival and economic impact of rapid prostate-specific antigen doubling time in patients with nonmetastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2023. https:\/\/doi.org\/10.1016\/j.clgc.2023.01.003.","journal-title":"Clin Genitourin Cancer"},{"key":"1594_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30030240","author":"W Zhang","year":"2023","unstructured":"Zhang W, Guh DP, Mohammadi T, Pataky RE, Tam ACT, Lynd LD, et al. Health care costs attributable to prostate cancer in British Columbia, Canada: a population-based cohort study. Curr Oncol. 2023. https:\/\/doi.org\/10.3390\/curroncol30030240.","journal-title":"Curr Oncol"},{"key":"1594_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028214","author":"L Zhuo","year":"2019","unstructured":"Zhuo L, Cheng Y, Pan Y, Zong J, Sun W, Xu L, et al. Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database. BMJ Open. 2019. https:\/\/doi.org\/10.1136\/bmjopen-2018-028214.","journal-title":"BMJ Open"},{"key":"1594_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00719","author":"L Bai","year":"2020","unstructured":"Bai L, Wushouer H, Huang C, Luo Z, Guan X, Shi L. Health care utilization and costs of patients with prostate cancer in China based on National Health Insurance database from 2015 to 2017. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.00719.","journal-title":"Front Pharmacol"},{"key":"1594_CR45","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2320001","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu C, Liu C, Lu Y, Ban L, Niu Y. Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study. J Med Econ. 2024. https:\/\/doi.org\/10.1080\/13696998.2024.2320001.","journal-title":"J Med Econ"},{"key":"1594_CR46","doi-asserted-by":"publisher","DOI":"10.36401\/JQSH-22-20","author":"GH Elsisi","year":"2023","unstructured":"Elsisi GH, El-Attar MM, Ismaeil SM, El-Shater ME, Kirollos MG, Sedrak AS, et al. Estimation of prostate cancer cost in Egypt from a societal perspective. Global Journal on Quality and Safety in Healthcare. 2023. https:\/\/doi.org\/10.36401\/JQSH-22-20.","journal-title":"Global Journal on Quality and Safety in Healthcare"},{"key":"1594_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-07817-6","author":"C Ngcamphalala","year":"2022","unstructured":"Ngcamphalala C, \u00d6stensson E, Ginindza TG. The economic burden of prostate cancer in Eswatini. BMC Health Serv Res. 2022. https:\/\/doi.org\/10.1186\/s12913-022-07817-6.","journal-title":"BMC Health Serv Res"},{"key":"1594_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-020-00219-6","author":"K Kreis","year":"2021","unstructured":"Kreis K, Horenkamp-Sonntag D, Schneider U, Zeidler J, Glaeske G, Weissbach L. Treatment-related healthcare costs of metastatic castration-resistant prostate cancer in Germany: a claims data study. Pharmacoecon Open. 2021. https:\/\/doi.org\/10.1007\/s41669-020-00219-6.","journal-title":"Pharmacoecon Open"},{"key":"1594_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-021-01006-w","author":"T Michaeli","year":"2022","unstructured":"Michaeli T, Michaeli D. Prostate cancer follow-up costs in Germany from 2000 to 2015. J Cancer Surviv. 2022. https:\/\/doi.org\/10.1007\/s11764-021-01006-w.","journal-title":"J Cancer Surviv"},{"key":"1594_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08476-3","author":"E Wiafe","year":"2022","unstructured":"Wiafe E, Mensah KB, Appiah KAA, Oosthuizen F, Bangalee V. The direct cost incurred by patients and caregivers in diagnosing and managing prostate cancer in Ghana. BMC Health Serv Res. 2022. https:\/\/doi.org\/10.1186\/s12913-022-08476-3.","journal-title":"BMC Health Serv Res"},{"key":"1594_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2015.03.020","author":"A Inotai","year":"2015","unstructured":"Inotai A, Abonyi-T\u00f3th Z, Rokszin G, Vok\u00f3 Z. Prognosis, cost, and occurrence of colorectal, lung, breast, and prostate cancer in Hungary. Value Health Reg Issues. 2015. https:\/\/doi.org\/10.1016\/j.vhri.2015.03.020.","journal-title":"Value Health Reg Issues"},{"key":"1594_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.11.001","author":"MM Mojahedian","year":"2019","unstructured":"Mojahedian MM, Toroski M, Keshavarz K, Aghili M, Zeyghami S, Nikfar S. Estimating the cost of illness of prostate cancer in Iran. Clin Ther. 2019. https:\/\/doi.org\/10.1016\/j.clinthera.2018.11.001.","journal-title":"Clin Ther"},{"key":"1594_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-023-00493-1","author":"F Alinezhad","year":"2023","unstructured":"Alinezhad F, Khalili F, Zare H, Lu C, Mahmoudi Z, Yousefi M. Financial burden of prostate cancer in the Iranian population: a cost of illness and financial risk protection analysis. Cost Eff Resour Alloc. 2023. https:\/\/doi.org\/10.1186\/s12962-023-00493-1.","journal-title":"Cost Eff Resour Alloc"},{"key":"1594_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-024-06913-6","author":"B Darvishi Teli","year":"2024","unstructured":"Darvishi Teli B, Rezapour A, Behzadifar M, Azari S, Ehsanzadeh SJ, Behzadifar M. The economic burden of prostate cancer in Iran: a cross-sectional cost-of-illness study. BMC Res Notes. 2024. https:\/\/doi.org\/10.1186\/s13104-024-06913-6.","journal-title":"BMC Res Notes"},{"key":"1594_CR55","doi-asserted-by":"publisher","DOI":"10.4103\/jehp.jehp_928_21","author":"A Jabbari","year":"2023","unstructured":"Jabbari A, Hadian M, Mazaheri E, Jelodar ZK. The economic cost of cancer treatment in Iran. J Educ Health Promot. 2023. https:\/\/doi.org\/10.4103\/jehp.jehp_928_21.","journal-title":"J Educ Health Promot"},{"key":"1594_CR56","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S148323","author":"U Restelli","year":"2017","unstructured":"Restelli U, Ceresoli GL, Croce D, Evangelista L, Maffioli LS, Gianoncelli L, et al. Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. Cancer Manag Res. 2017. https:\/\/doi.org\/10.2147\/CMAR.S148323.","journal-title":"Cancer Manag Res"},{"key":"1594_CR57","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462322003336","author":"L Borsoi","year":"2023","unstructured":"Borsoi L, Ciani O, Fornarini G, Oderda M, Sciarra A, Vetrini D, et al. Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy. Int J Technol Assess Health Care. 2023. https:\/\/doi.org\/10.1017\/S0266462322003336.","journal-title":"Int J Technol Assess Health Care"},{"key":"1594_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-015-1103-x","author":"T Kitazawa","year":"2015","unstructured":"Kitazawa T, Matsumoto K, Fujita S, Seto K, Hanaoka S, Hasegawa T. Cost of illness of the prostate cancer in Japan--a time-trend analysis and future projections. BMC Health Serv Res. 2015. https:\/\/doi.org\/10.1186\/s12913-015-1103-x.","journal-title":"BMC Health Serv Res"},{"key":"1594_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03683-3","author":"K Matsumoto","year":"2022","unstructured":"Matsumoto K, Hatakeyama Y, Seto K, Onishi R, Hirata K, Wu Y, et al. Cost of illness in a super-aged society-comparison of breast, lung, and prostate cancer in Japan. BMC Geriatr. 2022. https:\/\/doi.org\/10.1186\/s12877-022-03683-3.","journal-title":"BMC Geriatr"},{"key":"1594_CR60","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2018.19.1.21","author":"T Satoh","year":"2018","unstructured":"Satoh T, Ledesma D, Yoshihara N. The economic burden of metastatic castration resistant prostate cancer and skeletal related events in Japanese University Hospitals. Asian Pac J Cancer Prev. 2018. https:\/\/doi.org\/10.22034\/APJCP.2018.19.1.21.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1594_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae177","author":"T Kimura","year":"2025","unstructured":"Kimura T, Ito T, Taguchi T, Hattori K, Matsuyama R. Initial treatment and resource utilization among patients with metastatic-castration sensitive prostate cancer in Japan: a retrospective real-world study. Jpn J Clin Oncol. 2025. https:\/\/doi.org\/10.1093\/jjco\/hyae177.","journal-title":"Jpn J Clin Oncol"},{"key":"1594_CR62","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000330","author":"T Blakely","year":"2015","unstructured":"Blakely T, Atkinson J, Kvizhinadze G, Wilson N, Davies A, Clarke P. Patterns of cancer care costs in a country with detailed individual data. Med Care. 2015. https:\/\/doi.org\/10.1097\/MLR.0000000000000330.","journal-title":"Med Care"},{"key":"1594_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08526-w","author":"G Bj\u00f8rnelv","year":"2022","unstructured":"Bj\u00f8rnelv G, Hagen TP, Forma L, Aas E. Care pathways at end-of-life for cancer decedents: registry based analyses of the living situation, healthcare utilization and costs for all cancer decedents in Norway in 2009\u20132013 during their last 6 months of life. BMC Health Serv Res. 2022. https:\/\/doi.org\/10.1186\/s12913-022-08526-w.","journal-title":"BMC Health Serv Res"},{"key":"1594_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53878-4","author":"B \u0141yszczarz","year":"2024","unstructured":"\u0141yszczarz B. Productivity losses from short-term work absence due to neoplasms in Poland. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-024-53878-4.","journal-title":"Sci Rep"},{"key":"1594_CR65","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.001","author":"KS Lee","year":"2015","unstructured":"Lee KS, Chang HS, Lee SM, Park EC. Economic Burden of Cancer in Korea during 2000\u20132010. Cancer Res Treat. 2015. https:\/\/doi.org\/10.4143\/crt.2014.001.","journal-title":"Cancer Res Treat"},{"key":"1594_CR66","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.200113","author":"YS Ha","year":"2021","unstructured":"Ha YS, Kim SY, Chung JI, Choi H, Kim JH, Yu HS, et al. Trends in end-of-life resource utilization and costs among prostate cancer patients from 2006 to 2015: a nationwide population-based study. World J Mens Health. 2021. https:\/\/doi.org\/10.5534\/wjmh.200113.","journal-title":"World J Mens Health"},{"key":"1594_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2020.12.035","author":"O Ibarrondo","year":"2022","unstructured":"Ibarrondo O, Lizeaga G, Mart\u00ednez-Llorente JM, Larra\u00f1aga I, Soto-Gordoa M, \u00c1lvarez-L\u00f3pez I. Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component. Gac Sanit. 2022. https:\/\/doi.org\/10.1016\/j.gaceta.2020.12.035.","journal-title":"Gac Sanit"},{"key":"1594_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090580","author":"MJ Carreras","year":"2023","unstructured":"Carreras MJ, Tom\u00e1s-Guill\u00e9n E, Farriols A, Renedo-Mir\u00f3 B, Valdivia C, Vidal J, et al. Use of drugs in clinical practice and the associated cost of cancer treatment in adult patients with solid tumors: a 10-year retrospective cohort study. Curr Oncol. 2023. https:\/\/doi.org\/10.3390\/curroncol30090580.","journal-title":"Curr Oncol"},{"key":"1594_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298764","author":"J Darb\u00e0","year":"2024","unstructured":"Darb\u00e0 J, Ascanio M. Prostate cancer in Spain: a retrospective database analysis of hospital incidence and the direct medical costs. PLoS ONE. 2024. https:\/\/doi.org\/10.1371\/journal.pone.0298764.","journal-title":"PLoS ONE"},{"key":"1594_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-05265-8","author":"S Hao","year":"2020","unstructured":"Hao S, \u00d6stensson E, Eklund M, Gr\u00f6nberg H, Nordstr\u00f6m T, Heintz E, et al. The economic burden of prostate cancer\u2014a Swedish prevalence-based register study. BMC Health Serv Res. 2020. https:\/\/doi.org\/10.1186\/s12913-020-05265-8.","journal-title":"BMC Health Serv Res"},{"key":"1594_CR71","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2020.1851762","author":"J Svensson","year":"2021","unstructured":"Svensson J, Lissbrant IF, Gauffin O, Hj\u00e4lm-Eriksson M, Kilany S, Fagerlund K, et al. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scand J Urol. 2021. https:\/\/doi.org\/10.1080\/21681805.2020.1851762.","journal-title":"Scand J Urol"},{"key":"1594_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036341","author":"SY Huang","year":"2020","unstructured":"Huang SY, Chen HM, Liao KH, Ko BS, Hsiao FY. Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007-2017. BMJ Open. 2020. https:\/\/doi.org\/10.1136\/bmjopen-2019-036341.","journal-title":"BMJ Open"},{"key":"1594_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310613","author":"PC Liu","year":"2025","unstructured":"Liu PC, Lin YS, Ou YC, Hsu CY, Tung MC, Chiu YM. Comprehensive analysis of prostate cancer life expectancy, loss of life expectancy, and healthcare expenditures: Taiwan national cohort study spanning 2008 to 2019. PLoS ONE. 2025. https:\/\/doi.org\/10.1371\/journal.pone.0310613.","journal-title":"PLoS ONE"},{"key":"1594_CR74","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0026","author":"R Ter Heine","year":"2017","unstructured":"Ter Heine R, Frederix GW, Geenen JW, H\u00f6vels AM, van Vulpen M, Kooistra A, et al. Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands. J Comp Eff Res. 2017. https:\/\/doi.org\/10.2217\/cer-2017-0026.","journal-title":"J Comp Eff Res"},{"key":"1594_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.70003","author":"G Pantoja","year":"2025","unstructured":"Pantoja G, Wibben A, Bhagaloo V, Seetaram S, Persaud S. The significant costs of prostate cancer management-an analysis from a Caribbean hospital. BJUI Compass. 2025. https:\/\/doi.org\/10.1002\/bco2.70003.","journal-title":"BJUI Compass"},{"key":"1594_CR76","doi-asserted-by":"publisher","DOI":"10.1177\/0269216315595203","author":"J Round","year":"2015","unstructured":"Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat Med. 2015. https:\/\/doi.org\/10.1177\/0269216315595203.","journal-title":"Palliat Med"},{"key":"1594_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.644","author":"PS Hall","year":"2015","unstructured":"Hall PS, Hamilton P, Hulme CT, Meads DM, Jones H, Newsham A, et al. Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data. Br J Cancer. 2015. https:\/\/doi.org\/10.1038\/bjc.2014.644.","journal-title":"Br J Cancer"},{"key":"1594_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.77","author":"M Laudicella","year":"2016","unstructured":"Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer. 2016. https:\/\/doi.org\/10.1038\/bjc.2016.77.","journal-title":"Br J Cancer"},{"key":"1594_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-021-00307-1","author":"D Rana","year":"2022","unstructured":"Rana D, Geue C, Baillie K, Pan J, Mueller T, Laskey J, et al. Healthcare costs for metastatic castration-resistant prostate cancer patients treated with Abiraterone or Enzalutamide. PharmacoEconomics - Open. 2022. https:\/\/doi.org\/10.1007\/s41669-021-00307-1.","journal-title":"PharmacoEconomics - Open"},{"key":"1594_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv382","author":"Z Zheng","year":"2015","unstructured":"Zheng Z, Yabroff KR, Guy GP Jr, Han X, Li C, Banegas MP, et al. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst. 2015. https:\/\/doi.org\/10.1093\/jnci\/djv382.","journal-title":"J Natl Cancer Inst"},{"key":"1594_CR81","doi-asserted-by":"publisher","DOI":"10.36469\/9844","author":"PJ Mallow","year":"2016","unstructured":"Mallow PJ, Chen J, Rizzo JA, Penrod JR, Trudel GC, Zyczynski TM. The direct healthcare expenditures of prostate cancer by disease severity: evidence from US National Survey Data. J Health Econ Outcomes Res. 2016. https:\/\/doi.org\/10.36469\/9844.","journal-title":"J Health Econ Outcomes Res"},{"key":"1594_CR82","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0327","author":"JA McDougall","year":"2016","unstructured":"McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, et al. The clinical and economic impacts of skeletal-related events among Medicare enrollees with prostate cancer metastatic to bone. Oncologist. 2016. https:\/\/doi.org\/10.1634\/theoncologist.2015-0327.","journal-title":"Oncologist"},{"key":"1594_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29743","author":"AA Laviana","year":"2016","unstructured":"Laviana AA, Ilg AM, Veruttipong D, Tan HJ, Burke MA, Niedzwiecki DR, et al. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. Cancer. 2016. https:\/\/doi.org\/10.1002\/cncr.29743.","journal-title":"Cancer"},{"key":"1594_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.07.006","author":"MA Dinan","year":"2016","unstructured":"Dinan MA, Li Y, Zhang Y, Stewart SB, Curtis LH, George DJ, et al. Resource use in the last year of life among patients who died with versus of prostate cancer. Clin Genitourin Cancer. 2016. https:\/\/doi.org\/10.1016\/j.clgc.2015.07.006.","journal-title":"Clin Genitourin Cancer"},{"key":"1594_CR85","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S143148","author":"L Iadeluca","year":"2017","unstructured":"Iadeluca L, Mardekian J, Chander P, Hopps M, Makinson GT. The burden of selected cancers in the US: health behaviors and health care resource utilization. Cancer Manag Res. 2017. https:\/\/doi.org\/10.2147\/CMAR.S143148.","journal-title":"Cancer Manag Res"},{"key":"1594_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30784","author":"TT Li","year":"2017","unstructured":"Li TT, Shore ND, Mehra M, Todd MB, Saadi R, Leblay G, et al. Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease. Cancer. 2017. https:\/\/doi.org\/10.1002\/cncr.30784.","journal-title":"Cancer"},{"key":"1594_CR87","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1333512","author":"F Kariburyo","year":"2017","unstructured":"Kariburyo F, Wang Y, Cheng IE, Wang L, Morgenstern D, Asner I, et al. Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system. J Med Econ. 2017. https:\/\/doi.org\/10.1080\/13696998.2017.1333512.","journal-title":"J Med Econ"},{"key":"1594_CR88","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12760","author":"AB Chen","year":"2018","unstructured":"Chen AB, Li L, Cronin AM, Brooks GA, Kavanagh BD, Schrag D. Estimating costs of care attributable to cancer: does the choice of comparison group matter? Health Serv Res. 2018. https:\/\/doi.org\/10.1111\/1475-6773.12760.","journal-title":"Health Serv Res"},{"key":"1594_CR89","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12745","author":"CT Chen","year":"2018","unstructured":"Chen CT, Li L, Brooks G, Hassett M, Schrag D. Medicare spending for breast, prostate, lung, and colorectal cancer patients in the year of diagnosis and year of death. Health Serv Res. 2018. https:\/\/doi.org\/10.1111\/1475-6773.12745.","journal-title":"Health Serv Res"},{"key":"1594_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.02.008","author":"Y Zhong","year":"2018","unstructured":"Zhong Y, Valderrama A, Yao J, Donga P, Bilir P, Neumann PJ. Economic evaluation of treating skeletal-related events among prostate cancer patients. Value Health. 2018. https:\/\/doi.org\/10.1016\/j.jval.2017.02.008.","journal-title":"Value Health"},{"key":"1594_CR91","unstructured":"Tangirala K, Appukkuttan S, Simmons S. Costs and healthcare resource utilization associated with hospital admissions of patients with metastatic or nonmetastatic prostate cancer. Am Health Drug Benefits. 2019;12(6):306\u201312."},{"key":"1594_CR92","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.19109","author":"NM Schultz","year":"2019","unstructured":"Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, et al. Health care resource utilization and costs associated with corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis. J Manag Care Spec Pharm. 2019. https:\/\/doi.org\/10.18553\/jmcp.2019.19109.","journal-title":"J Manag Care Spec Pharm"},{"key":"1594_CR93","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.3-b.s1","author":"L Wen","year":"2019","unstructured":"Wen L, Yao J, Valderrama A. Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases. J Manag Care Spec Pharm. 2019. https:\/\/doi.org\/10.18553\/jmcp.2019.25.3-b.s1.","journal-title":"J Manag Care Spec Pharm"},{"key":"1594_CR94","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3701","author":"JG Trogdon","year":"2019","unstructured":"Trogdon JG, Falchook AD, Basak R, Carpenter WR, Chen RC. Total medicare costs associated with diagnosis and treatment of prostate cancer in elderly men. JAMA Oncol. 2019. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3701.","journal-title":"JAMA Oncol"},{"key":"1594_CR95","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-00185-8","author":"S Appukkuttan","year":"2020","unstructured":"Appukkuttan S, Tangirala K, Babajanyan S, Wen L, Simmons S, Shore N. A retrospective claims analysis of advanced prostate cancer costs and resource use. Pharmacoecon Open. 2020. https:\/\/doi.org\/10.1007\/s41669-019-00185-8.","journal-title":"Pharmacoecon Open"},{"key":"1594_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2020.02.014","author":"C Tang","year":"2020","unstructured":"Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, et al. Costs and complications after a diagnosis of prostate cancer treated with time-efficient modalities: an analysis of national medicare data. Pract Radiat Oncol. 2020. https:\/\/doi.org\/10.1016\/j.prro.2020.02.014.","journal-title":"Pract Radiat Oncol"},{"key":"1594_CR97","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1705313","author":"A Shah","year":"2020","unstructured":"Shah A, Shah R, Kebede N, Mohamed A, Botteman M, Waldeck R, et al. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy. J Med Econ. 2020. https:\/\/doi.org\/10.1080\/13696998.2019.1705313.","journal-title":"J Med Econ"},{"key":"1594_CR98","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1678171","author":"B Wu","year":"2020","unstructured":"Wu B, Li SS, Song J, Pericone CD, Behl AS, Dawson NA. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population. J Med Econ. 2020. https:\/\/doi.org\/10.1080\/13696998.2019.1678171.","journal-title":"J Med Econ"},{"key":"1594_CR99","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0639","author":"G Gustavsen","year":"2020","unstructured":"Gustavsen G, Gullet L, Cole D, Lewine N, Bishoff JT. Economic burden of illness associated with localized prostate cancer in the United States. Future Oncol. 2020. https:\/\/doi.org\/10.2217\/fon-2019-0639.","journal-title":"Future Oncol"},{"key":"1594_CR100","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002121","author":"CJ Ryan","year":"2021","unstructured":"Ryan CJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, et al. Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States. J Urol. 2021. https:\/\/doi.org\/10.1097\/JU.0000000000002121.","journal-title":"J Urol"},{"key":"1594_CR101","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.27784","author":"NG Zaorsky","year":"2021","unstructured":"Zaorsky NG, Khunsriraksakul C, Acri SL, Liu DJ, Ba DM, Lin JL, et al. Medical service use and charges for cancer care in 2018 for privately insured patients younger than 65 years in the US. JAMA Netw Open. 2021. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.27784.","journal-title":"JAMA Netw Open"},{"key":"1594_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2020.11.004","author":"CJ Magnani","year":"2021","unstructured":"Magnani CJ, Bievre N, Baker LC, Brooks JD, Blayney DW, Hernandez-Boussard T. Real-world evidence to estimate prostate cancer costs for first-line treatment or active surveillance. Eur Urol Open Sci. 2021. https:\/\/doi.org\/10.1016\/j.euros.2020.11.004.","journal-title":"Eur Urol Open Sci"},{"key":"1594_CR103","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac141","author":"YT Shih","year":"2022","unstructured":"Shih YT, Xu Y, Bradley C, Giordano SH, Yao J, Yabroff KR. Costs around the first year of diagnosis for 4 common cancers among the privately insured. J Natl Cancer Inst. 2022. https:\/\/doi.org\/10.1093\/jnci\/djac141.","journal-title":"J Natl Cancer Inst"},{"key":"1594_CR104","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2047536","author":"SR Reddy","year":"2022","unstructured":"Reddy SR, Broder MS, Chang E, Paydar C, Chung KC, Kansal AR. Cost of cancer management by stage at diagnosis among Medicare beneficiaries. Curr Med Res Opin. 2022. https:\/\/doi.org\/10.1080\/03007995.2022.2047536.","journal-title":"Curr Med Res Opin"},{"key":"1594_CR105","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.5.544","author":"QD Trinh","year":"2022","unstructured":"Trinh QD, Chaves LP, Feng Q, Zhu J, Sandin R, Abbott T. The cost impact of disease progression to metastatic castration-sensitive prostate cancer. J Manag Care Spec Pharm. 2022. https:\/\/doi.org\/10.18553\/jmcp.2022.28.5.544.","journal-title":"J Manag Care Spec Pharm"},{"key":"1594_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34905","author":"M Horn\u00fd","year":"2023","unstructured":"Horn\u00fd M, Yabroff KR, Filson CP, Zheng Z, Ekwueme DU, Richards TB, et al. The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance. Cancer. 2023. https:\/\/doi.org\/10.1002\/cncr.34905.","journal-title":"Cancer"},{"key":"1594_CR107","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02572-4","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, Davis MR, Epstein AJ, Arondekar B, Ivanova JI. Healthcare costs in men with metastatic castration-resistant prostate cancer: an analysis of US Medicare fee-for-service claims. Adv Ther. 2023. https:\/\/doi.org\/10.1007\/s12325-023-02572-4.","journal-title":"Adv Ther"},{"key":"1594_CR108","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2303890","author":"DR Kaye","year":"2024","unstructured":"Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Urosevic A, et al. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation. J Med Econ. 2024. https:\/\/doi.org\/10.1080\/13696998.2024.2303890.","journal-title":"J Med Econ"},{"key":"1594_CR109","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.7.684","author":"DR Kaye","year":"2024","unstructured":"Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, et al. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States. J Manag Care Spec Pharm. 2024. https:\/\/doi.org\/10.18553\/jmcp.2024.30.7.684.","journal-title":"J Manag Care Spec Pharm"},{"key":"1594_CR110","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2299179","author":"S Appukkuttan","year":"2024","unstructured":"Appukkuttan S, Yao J, Partridge J, Kong SX, Parkin J, Freedland SJ. Adverse events and costs among non-metastatic castration-resistant prostate cancer patients. J Med Econ. 2024. https:\/\/doi.org\/10.1080\/13696998.2023.2299179.","journal-title":"J Med Econ"},{"key":"1594_CR111","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2323901","author":"DR Kaye","year":"2024","unstructured":"Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, et al. Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States. J Med Econ. 2024. https:\/\/doi.org\/10.1080\/13696998.2024.2323901.","journal-title":"J Med Econ"},{"key":"1594_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph21111527","author":"AAN Bovell","year":"2024","unstructured":"Bovell AAN, Ngcamphalala C, Rhudd A, Ncayiyana J, Ginindza TG. The economic burden of prostate cancer in Antigua and Barbuda: a prevalence-based cost-of-illness analysis from the healthcare provider perspective. Int J Environ Res Public Health. 2024. https:\/\/doi.org\/10.3390\/ijerph21111527.","journal-title":"Int J Environ Res Public Health"},{"key":"1594_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201552","author":"DE Goldsbury","year":"2018","unstructured":"Goldsbury DE, Yap S, Weber MF, Veerman L, Rankin N, Banks E, et al. Health services costs for cancer care in Australia: estimates from the 45 and Up Study. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0201552.","journal-title":"PLoS ONE"},{"key":"1594_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19159473","author":"KMD Merollini","year":"2022","unstructured":"Merollini KMD, Gordon LG, Ho YM, Aitken JF, Kimlin MG. Cancer survivors\u2019 long-term health service costs in Queensland, Australia: results of a population-level data linkage study (Cos-Q). Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/ijerph19159473.","journal-title":"Int J Environ Res Public Health"},{"key":"1594_CR115","doi-asserted-by":"publisher","unstructured":"Babela R, Balaz V, Jr JB. Prostate cancer in Slovakia: last decade overview. Bratisl Lek Listy. 2024;125(12):835\u201343. https:\/\/doi.org\/10.4149\/bll_2024_128.","DOI":"10.4149\/bll_2024_128"},{"issue":"7","key":"1594_CR116","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14737167.2025.2505726","volume":"25","author":"E Bournakis","year":"2025","unstructured":"Bournakis E, Bournakis A, Zolota DV, Kostouros E, Zagouri F, Papatheodoridi AP, et al. Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece. Expert Rev Pharmacoecon Outcomes Res. 2025;25(7):1063\u201372. https:\/\/doi.org\/10.1080\/14737167.2025.2505726.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"1594_CR117","doi-asserted-by":"publisher","first-page":"287","DOI":"10.18553\/jmcp.2022.28.3.287","volume":"28","author":"GC Ko","year":"2022","unstructured":"Ko GC, Hansen R, Carlson J. Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis. J Manag Care Spec Pharm. 2022;28(3):287\u201395. https:\/\/doi.org\/10.18553\/jmcp.2022.28.3.287.","journal-title":"J Manag Care Spec Pharm"},{"key":"1594_CR118","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2023038","volume":"45","author":"S Lin","year":"2023","unstructured":"Lin S, Lin D, Li Y, Zhong L, Zhou W, Wu Y, et al. Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey. Epidemiol Health. 2023;45:e2023038. https:\/\/doi.org\/10.4178\/epih.e2023038.","journal-title":"Epidemiol Health"},{"issue":"2","key":"1594_CR119","first-page":"107","volume":"88","author":"S Maroongroge","year":"2015","unstructured":"Maroongroge S, Kim SP, Mougalian S, Johung K, Decker RH, Soulos PR, et al. The cost of cancer-related physician services to Medicare. Yale J Biol Med. 2015;88(2):107\u201314.","journal-title":"Yale J Biol Med"},{"key":"1594_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08457-6","author":"N McGarvey","year":"2022","unstructured":"McGarvey N, Gitlin M, Fadli E, Chung KC. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res. 2022. https:\/\/doi.org\/10.1186\/s12913-022-08457-6.","journal-title":"BMC Health Serv Res"},{"key":"1594_CR121","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70226","author":"H Miura","year":"2024","unstructured":"Miura H, Yamamoto H, Okuyama Y, Ishi N, Tanaka R, Oishi T, et al. Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med. 2024. https:\/\/doi.org\/10.1002\/cam4.70226.","journal-title":"Cancer Med"},{"key":"1594_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102427","volume":"1","author":"TJ Murtola","year":"2025","unstructured":"Murtola TJ, Hakkarainen T, Lahelma M, Pennanen P, Leskel\u00e4 RL, Pietil\u00e4 M, et al. Healthcare resource use and costs of localized prostate cancer patients in Finland. Clin Genitourin Cancer. 2025;1:102427. https:\/\/doi.org\/10.1016\/j.clgc.2025.102427.","journal-title":"Clin Genitourin Cancer"},{"key":"1594_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2022.02.002","volume":"31","author":"A Nahvijou","year":"2022","unstructured":"Nahvijou A, Daroudi R, Javan-Noughabi J, Dehdarirad H, Faramarzi A. The lost productivity cost of premature mortality owing to cancers in Iran: evidence from the GLOBOCAN 2012 to 2018 estimates. Value Health Reg Issues. 2022;31:1\u20139. https:\/\/doi.org\/10.1016\/j.vhri.2022.02.002.","journal-title":"Value Health Reg Issues"},{"key":"1594_CR124","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01260-x","author":"K Ramaswamy","year":"2020","unstructured":"Ramaswamy K, Lechpammer S, Mardekian J, Huang A, Schultz NM, Sandin R, et al. Economic outcomes in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Adv Ther. 2020. https:\/\/doi.org\/10.1007\/s12325-020-01260-x.","journal-title":"Adv Ther"},{"key":"1594_CR125","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0774-1","author":"NM Schultz","year":"2018","unstructured":"Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, et al. Treatment duration, healthcare resource utilization, and costs among chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer treated with Enzalutamide or Abiraterone Acetate: a retrospective claims analysis. Adv Ther. 2018. https:\/\/doi.org\/10.1007\/s12325-018-0774-1.","journal-title":"Adv Ther"},{"key":"1594_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114072","volume":"204","author":"M Stucki","year":"2024","unstructured":"Stucki M, Dosch S, Gn\u00e4dinger M, Graber SM, Huber CA, Lenzin G, et al. Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - a claims data analysis. Eur J Cancer. 2024;204:114072. https:\/\/doi.org\/10.1016\/j.ejca.2024.114072.","journal-title":"Eur J Cancer"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01594-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01594-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01594-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:07:53Z","timestamp":1777111673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01594-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":126,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01594-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval and patient consent were not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"JD contributed to the investigation by interpreting the economic burden caused by prostate cancer and was a major contributor in the intellectual content revision. MA and AR searched for articles, analysed and interpreted the statistical data, and were major contributors in writing the manuscript. All authors have read and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}